newsfilter
← Latest News
Business Wire·

Covidien’s HawkOne™ Directional Atherectomy System Receives FDA 510(K) Clearance for the Treatment of Peripheral Arterial Disease

DUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced U.S. Food and Drug Administration 510(k) clearance for the HawkOne™ directional atherectomy system. The latest addition to Covidien’s directional atherectomy portfolio, the HawkOne™ system provides physicians with an enhanced cutting mechanism to more effectively treat the widest variety of plaque in patients with peripheral arterial disease (PAD).